Clinitech Laboratory Ltd
CTLLABBSE
₹32.00▲ +0.00 (+0.00%)
Whole company worth₹7 Cr
Price for ₹1 of profit₹17
1-year range₹29 – ₹47
This price may be out of date. Last traded ₹32.00 on 7 Oct 2026 (13 days ago). Not a live price.
The short version
A steadily growing, thinly profitable business — priced in line with what it earns.
What Clinitech Laboratory does
Incorporated in 1990, Clinitech Laboratory Ltd is in the business of providing pathology and related healthcare services.
Worked out from Clinitech Laboratory's own filed results and exchange data, in plain words. Where a finance term matters, we say what it means.
01What does it do?
Clinitech Laboratory is a micro-sized company in healthcare service provider.
Incorporated in 1990, Clinitech Laboratory Ltd is in the business of providing pathology and related healthcare services.
- Whole company is worth
- ₹7.3 crore
- Run by
- Jagdish Umakant Nayak
- Shareholders
- 267 people
- Listed since
- 2024
A very small company by stock-market value — prices can swing hard and trading can be thin.
02Is it growing?
Sales have grown 16% a year for 5 years.
At that pace a business doubles in size roughly every 5 years. Profit grew more slowly, at 1% a year — costs rose faster than sales.
Point at a bar for exact figures · amounts in ₹ crore
03Does it make money?
Out of every ₹100 it sells, it keeps ₹4.4 as profit.
Here is where the money from Clinitech Laboratory's sales went in FY26, the latest full year it has reported.
₹27
₹60
- ₹27Making or buying what it sellsraw materials, stock, goods bought for resale
- ₹60Running the businessstaff, rent, marketing, power and everything else
- ₹0.7Interest on its loansthe cost of borrowed money
- ₹5.4Wear and tearmachines, stores and buildings losing value over time
- ₹1.9Taxincome tax paid to the government
- ₹4.4Profit it keepswhat is left for the company's owners
On the money its owners have put in
It earns ₹5 a year on every ₹100 its owners have invested.
Bank FD ~₹6–7
₹5
₹-10₹0₹10₹20₹30₹40
That figure is called return on equity (ROE). Under ₹12 is a thin return for the risk of owning shares. For comparison, a bank fixed deposit pays roughly ₹6–7.
Does the profit turn into cash?
For every ₹100 of profit it reported, ₹-250 actually came in as cash.
Profit it reported₹1.2 Cr
Cash its business brought in−₹3.0 Cr
Over the last 3 years: ₹1.2 crore of profit but only −₹3.0 crore of cash. A wide gap like this is worth understanding before trusting the profit figure.
04Is the price high or low?
You pay ₹17 for every ₹1 of profit it makes in a year.
This is the P/E ratio: share price divided by a year's profit per share. A P/E of 17 means buyers are paying for about 17 years of today's profit up front.
The share price over the past year
It is 32% below its highest price of the past year and 12% above its lowest.
05Who owns it?
Its founders and parent group own 65 of every 100 shares — they control the company.
If the company were split into 100 equal shares, this is who would hold them. 267 people and institutions hold its shares.
As filed for the quarter ending 30 Sept 2026. Arrows show the change since the quarter before, in percentage points.
06What is going well, and what to watch
Two things going well, one thing worth watching.
Picked out of the numbers above by fixed rules — the same rules for every company — so nothing here is somebody's opinion.
Going well
- Sales have compounded at 16% a year.
- Has almost no debt — it is not at the mercy of lenders.
Worth watching
- Thinly traded — only about ₹1 lakh of shares change hands a day, so buying or selling can move the price.
07What happened lately?
Its latest quarter.
Jan–Mar 2026 is the most recent quarter it has reported. Each figure is compared with the same three months a year earlier, because many businesses sell more in some seasons than others.
Sales
₹4.4 Cr
Profit
₹0.1 Cr
No notable developments in the last few weeks.
Advanced view
Every number, every table, the full chart.
Ten years of statements, quarterly results, peers side by side, technical indicators, analyst estimates, bulk deals and filings.
Ask DoXy
Still have a question about Clinitech Laboratory?
This page describes Clinitech Laboratory using its reported figures and exchange data. It is for information only and is not investment advice or a recommendation to buy, sell or hold. DocStoX is not a SEBI-registered investment adviser or research analyst.
Clinitech Laboratory Ltd (CTLLAB): company summary
The company's revenue grew 15.3% annually, but net profit remained at ₹0 crore, with a net profit margin that fell 0.4 percentage points to 4.4%.
Clinitech Laboratory Ltd (CTLLAB) is a micro-cap Healthcare Services company valued at ₹7 crore operating in Healthcare Service Provider on the NSE and BSE.
- Recent price move
- Clinitech Laboratory Ltd last traded at ₹32, unchanged on the day.
- Financial performance
- The company's revenue grew 15.3% annually, but net profit remained at ₹0 crore, with a net profit margin that fell 0.4 percentage points to 4.4%. In the latest quarter, revenue rose 5.5% compared to the same quarter a year earlier, but net profit fell 29.4% despite remaining at ₹0 crore.
- Valuation multiples
- The stock trades at 17.5 times earnings, 0.83 times book value.
- Things to watch
- The company has not reported any net profit in the latest fiscal year or the latest quarter, and the net profit margin has declined. The stock is 32.1% below its 52-week high, and the company's profit growth over the past five years has been minimal at 1.0% annually.
- Where it stands
- The company's revenue has grown steadily, but net profit remains at zero, and the net profit margin has declined. The stock is significantly below its 52-week high, and profit growth has been weak over the past five years.
Summarised by DocStoX's model on 2026-10-18 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.
More Healthcare Services stocks · Healthcare Service Provider
Explore Clinitech Laboratory Ltd’s valuation
Free deep-dive tools · no sign-up
Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.
Clinitech Laboratory Ltd peers in Healthcare Services
Other Healthcare Services stocks on the NSE & BSE. See the full Healthcare Services sector list.
Related tools & concepts
Value Clinitech Laboratory Ltd with the ratios and calculators DocStoX uses in its analysis.
P/E RatioPrice to earningsReturn on Equity (ROE)ProfitabilityROCECapital efficiencyDebt to EquityLeverageP/B RatioPrice to bookNet Profit MarginBottom-line efficiencyDCF / Intrinsic ValueEstimate fair valueCAGR CalculatorAnnualised returnDividend YieldIncome on pricePosition SizeRisk-based sizingBrokerage CalculatorCharges on a tradeSIP CalculatorSystematic investing